Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Bristol-Myers ...

We recently compiled a list of the 13 Best Pharma Dividend Stocks To Buy In 2024. In this article, we are going to take a ...

Bristol Myers Squibb (BMY) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of the ...

According to Benzinga Pro, Bristol-Myers Squibb's peer group average for short interest as a percentage of float is 4.30%, ...

The U.S. Food and Drug Administration said on Friday that it has approved an injectable version of Bristol Myers Squibb's ...

Supported by world-class markets data from Dow Jones and FactSet, and partnering with Automated Insights, MarketWatch Automation brings you the latest, most pertinent content at record speed and with ...

Bristol-Myers Squibb has rebounded strongly in 2024, driven by key drug approvals and positive financial performance. See why ...

Bristol-Myers Squibb faces patent risks but has promising new drugs. Find out why BMY stock remains a "Buy" with strong ...

Bristol-Myers Squibb Co (BMY) stock saw a decline, ending the day at $57.68 which represents a decrease of $-0.32 or -0.55% from the prior close of $58. The stock opened at $57.65 and touched a low of ...

Pre-tax profits at the main Irish unit of pharma giant Bristol Myers Squibb last year declined by 42% to $3.97 billion (€3.82 ...

Shares of Bristol Myers Squibb Co. BMY slumped 0.55% to $57.68 Friday, on what proved to be an all-around poor trading ...

A big dividend yield for a few years doesn't mean much if it can't be sustained. Even though Bristol-Myers Squibb isn't generating a profit, it is generating healthy free cash flows that easily ...